NCT04229095View on ClinicalTrials.gov

Medication Development in Alcoholism: Suvorexant Versus Placebo

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

November 8, 2022

Study Completion Date

November 8, 2022

Conditions
Alcohol Use Disorder (AUD)
Interventions
DRUG

Suvorexant 20 mg

Single-dose administration of 20 mg suvorexant given on an inpatient clinical research unit

DRUG

Placebo oral tablet

Single-dose administration of placebo given on an inpatient clinical research unit

Trial Locations (1)

92037-4657

Scripps Research, La Jolla

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

The Scripps Research Institute

OTHER

NCT04229095 - Medication Development in Alcoholism: Suvorexant Versus Placebo | Biotech Hunter | Biotech Hunter